

DNDi Drugs for Neglected Diseases initiative
India Foundation

(CIN: U73100DL2016NPL300545)

Registered Office: PHD Chamber, 3rd Floor, 4/2 Siri Institutional Area, August Kranti Marg, New Delhi 110016, India
Ph: +91-11-45501795; E-mail: dndiindiafoundation@gmail.com

Dear Members / Directors / Statutory Auditor,

You are cordially invited to attend the second Annual General Meeting ("AGM") of the members of DNDi Drugs for Neglected Diseases Initiative India Foundation (the Company) to be held at shorter notice on Tuesday, August 21, 2018 at 4.00 P.M. (IST) at the registered office of the company situated at PHD Chambers, 3rd Floor, 4/2 Siri Institutional Area, August Kranti Marg, New Delhi - 110016, India.

The Notice of the meeting, containing the business to be transacted, is enclosed herewith.

By the order of Board

For and on behalf of **DNDi Drugs for Neglected Diseases Initiative India Foundation**



(Lalit Kant)

Director

DIN: 07242018

Address: B-95, Block B, Gulmohar Park, New Delhi - 110049, India

Date: August 21, 2018

Place: New Delhi

Enclosures:

1. Notice of the second AGM
2. Proxy form
3. Attendance slip

**DNDi Drugs for Neglected Diseases initiative
India Foundation**

(CIN: U73100DL2016NPL300545)

Registered Office: PHD Chamber, 3rd Floor, 4/2 Siri Institutional Area, August Kranti Marg, New Delhi 110016, India
Ph: +91-11-45501795; E-mail: dndiindiafoundation@gmail.com

NOTICE OF SECOND ANNUAL GENERAL MEETING

Notice is hereby given that second Annual General Meeting ("AGM") of the members of DNDi Drugs for Neglected Diseases Initiative India Foundation will be held at shorter notice on Tuesday, August 21, 2018 at 4.00 P.M. (IST) at the registered office of the company situated at PHD Chambers, 3rd Floor, 4/2 Siri Institutional Area, August Kranti Marg New Delhi - 110016, India to transact the following businesses:

ORDINARY BUSINESS:

1. To receive, consider and adopt the audited financial statements of the Company for the financial year ended on March 31, 2018 and the schedules and annexure thereto for the financial year ended on that date, together with report of auditors and directors thereon.
2. To ratify the re-appointment of M/s. Singh K.V. Gupta & Co. Chartered Accountants (ICAI firm registration no. 000133N) as statutory auditors and to fix their remuneration and to pass the following resolutions as ordinary resolutions thereof:

'RESOLVED THAT pursuant to the provisions of section 139 and other applicable provisions, if any, of the Companies Act, 2013 and the rules framed thereunder, as amended from time to time, and pursuant to the resolutions passed by the members at the first annual general meeting of the Company held on May 29, 2017, the re-appointment of M/s. Singh K.V. Gupta & Co., Chartered Accountants (ICAI firm registration no. 000133N), as the statutory auditors of the Company to hold office until the conclusion of the sixth annual general meeting (subject to ratification at every annual general meeting) be and is hereby ratified at a remuneration of 50,000.

RESOLVED FURTHER THAT the Directors of the Company be and are hereby severally authorized to inform the statutory auditors of the above ratification and to provide a certified true copy of these resolutions on behalf of the Company and to undertake all necessary steps including filings, if required, to be done with the concerned regulatory authorities as may considered necessary or expedient in this regard."

By the order of Board

For and on behalf of DNDi Drugs for Neglected Diseases Initiative India Foundation



(Lalit Kant)

Director

DIN: 07242018

Address: B-95, Block B, Gulmohar Park, New Delhi - 110049, India

Date: August 21, 2018

Place: New Delhi

DNDi Drugs for Neglected Diseases initiative
India Foundation

(CIN: U73100DL2016NPL300345)

Registered Office: PHD Chamber, 3rd Floor, 4/2 Siri Institutional Area, August Kranti Marg, New Delhi 110016, India
Ph: +91-11-45501795; E-mail: dndiindiafoundation@gmail.com

Notes:

- (1) **MEMBER ENTITLED TO ATTEND AND VOTE AT THE MEETING IS ENTITLED TO APPOINT A PROXY, OR, WHERE THAT IS ALLOWED, ONE OR MORE PROXIES, TO ATTEND AND VOTE ON A POLL INSTEAD OF HIMSELF / HERSELF AND THE PROXY SO APPOINTED SHALL BE A MEMBER OF THE COMPANY. PROXIES IN ORDER TO BE EFFECTIVE MUST BE RECEIVED AT THE REGISTERED OFFICE OF THE COMPANY NOT LESS THAN FORTY EIGHT HOURS BEFORE THE MEETING. A PROXY FORM FOR THE AGM IS ENCLOSED.**
- (2) Corporate Members intending to send their authorized representatives to attend the meeting are requested to send a duly certified copy of the board resolution to the Company, authorizing their representative to attend and vote on their behalf at the meeting.
- (3) Members/proxies/authorized representatives should bring the duly filled Attendance Slip enclosed herewith to attend the meeting.
- (4) Register of directors and key managerial personnel, maintained under Section 170 of the Companies Act, 2013, will be available for inspection by the members at the AGM.
- (5) The Register of contracts or arrangements in which the directors are interested, maintained under Section 189 of the Companies Act, 2013, will be available for inspection by the members at the AGM.
- (6) All documents referred to in the Notice will be available for inspection at the Company's registered office during normal business hours on working days up to the date of the AGM.
- (7) Members are requested to tender their attendance slips at the registration counters at the venue of the AGM and seek registration before entering the meeting hall. The members needs to furnish the printed 'attendance slip' along with a valid identity proof such as the PAN card, passport, AADHAR card or driving license, to enter the meeting hall.
- (8) The AGM is proposed to be held on a shorter notice. The member are requested to provide consent to hold the AGM at a shorter notice.

DNDi Drugs for Neglected Diseases initiative

India Foundation

(CIN: U73100DL2016NPL300545)

Registered Office: PHD Chamber, 3rd Floor, 4/2 Siri Institutional Area, August Kranti Marg, New Delhi 110016, India

Ph: +91-11-45501795; E-mail: dndiindiafoundation@gmail.com

Form No. MGT-11

Proxy form

(Pursuant to section 105 (6) of the Companies Act, 2013 and rule 19(3) of the Companies (Management and Administration) Rules, 2014)

CIN : U73100DL2016NPL300545
Name of the company : DNDi Drugs For Neglected Diseases Initiative India Foundation
Registered Office : PHD Chamber, 3rd Floor, 4/2, Institutional Area, August Kranti Marg, New Delhi - 110016, India

Name of the member (s) :

Registered address :

E-mail Id :

Folio No./Client Id :

DP ID :

I/We, being the member(s) the above named company, hereby appoint

1. Name : _____
Address : _____
E-mail Id : _____
Signature : _____ or failing him

2. Name : _____
Address : _____
E-mail Id : _____
Signature : _____ or failing him

3. Name : _____
Address : _____
E-mail Id : _____
Signature : _____

as my/our proxy to attend and vote (on a poll) for me/us and on my/our behalf at the Annual General Meeting of the company, to be held on Tuesday, August 21, 2018 at registered office of the company situated at PHD Chambers, 3rd Floor, 4/2 Siri Institutional Area, August Kranti Marg New Delhi - 110016, India, at 4.00 P.M. (IST) and at any adjournment thereof in respect of such resolutions as are indicated below :

Resolution No.

1. _____
2. _____
3. _____

Signed this ____ day of ____ 20__

Signature of Member

Signature of Proxy holder (s)

Affix Revenue
Stamp

Note: This form of proxy in order to be effective should be duly completed and deposited at the Registered Office of the Company, not less than 48 hours before the commencement of the Meeting.

**DNDi Drugs for Neglected Diseases initiative
India Foundation**

(CIN: U73100DL2016NPL100545)

Registered Office: PHD Chamber, 3rd Floor, 4/2 Siri Institutional Area, August Kranti Marg, New Delhi 110016, India
Ph: +91-11-45501795; E-mail: dndiindiafoundation@gmail.com

DIRECTORS' REPORT

Dear Members

Your directors have the pleasure to present the second report of the directors (the "Report") of your Company together with the Audited Annual Accounts for the financial year ended 31st March, 2018.

Financial Highlights

Particulars	(Figures in Rs.)	
	Financial Year ended on March 31, 2018	Financial Year ended on March 31, 2017
Total Income	350	64,143
Total Expenditure	38,483	1,04,020
Surplus (Deficit) for the year	(38,133)	(39,877)

State of Company's Affairs

DNDi Drugs for Neglected Diseases Initiative India Foundation (the Company), a not for profit company, within the meaning of section 8 of the Companies Act 2013. The prime focus of the Company is to provide support and to stimulate research and development, primarily of drugs, as well as vaccines and diagnostics for patients suffering from neglected diseases.

The Company is also in process of making application for prior permission for receiving foreign contribution under the provisions of The Foreign Contribution Regulation Act 2010 (FCRA)

Once FCRA permissions is in place, Your Directors are optimistic about company's operations and hopeful of better performance with increased grants/donations in next year

Material changes and commitment, if any, affecting the financial position of the Company

Save as mentioned elsewhere in this Report, no material changes and commitments affecting the financial position of the Company have occurred between the end of the financial year of the Company and the date of this Report.

Public Deposits

During the year under review, your Company did not accept any deposits in terms of the provisions of section 73 of the Companies Act, 2013 read with Companies (Acceptance of Deposits) Rules, 2014.

Number of meetings of the Board held during the financial year and attendance by Directors

During the year under review, two Board meetings were held on May 29, 2017 and November 23, 2017. The details of the Board meetings attended during the financial year by the Directors of the Company are as follows:

Date of the Board meeting	Unni Krishnan Karunakara	Lalit Kant	Shyam Sundar Agrawal
May 29, 2017	Yes	Yes	Yes
November 23, 2017	No	Yes	Yes

Conservation of Energy, Technology Absorption, Foreign Exchange Earnings and Outgo

- A. **Conservation of energy:** Since the Company is not engaged in any manufacturing activity, issues relating to conservation of energy and technology absorption are not quite relevant to its functioning.

DNDi Drugs for Neglected Diseases initiative
India Foundation

(CIN: U73100DL2016NPL300545)

Registered Office: PHD Chamber, 3rd Floor, 4/2 Siri Institutional Area, August Kranti Marg, New Delhi 110016, India
Ph: +91-11-45501795; E-mail: dndiindiafoundation@gmail.com

B. Technology absorption: Since the Company is not engaged in any manufacturing activity, issues relating to conservation of energy and technology absorption are not quite relevant to its functioning.

C. Foreign exchange earnings and Outgo:

Earnings in foreign exchange (actual inflows):	Nil
Expenditure in foreign currency (actual outflows):	Nil

Extract of Annual Return

The extract of Annual Return pursuant to the provisions of Section 92 read with Rule 12 of the Companies (Management and administration) Rules, 2014 is appended as **Annexure A**.

Transfer to reserves

No amount was transferred to the reserves during the financial year ended 31st March 2018.

Particulars of contracts or arrangements made with related parties

The Company did not enter into any contracts or arrangements with related parties referred to in Section 188(1) of the Companies Act, 2013.

Particulars of loans, guarantees or investments made under section 186 of the Companies Act, 2013

The Company did not provide any loan, guarantee or investment pursuant to section 186 of the Companies Act, 2013.

Directors and Key Managerial Personnel

There has been no change in the composition of the directors of the Company during the year under review. Dr. Lalit Kant, Dr. Unni Krishnan Karunakara and Dr. Shyam Sundar Agarwal are the directors of the Company as on the date of this report.

Statement of particulars of employees pursuant to provisions of rule 5(2) & (3) of Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014

The Company had no employees during the year under review.

Directors' Responsibility Statement

In terms of the provisions of section 134 (5) of the Companies Act, 2013, and to the best of their knowledge and belief and according to the information and explanations obtained by them and save as mentioned elsewhere in this Report, the attached Annual Accounts and the Auditors' Report thereon, your Directors confirm that:

- (a) in the preparation of the annual accounts, the applicable accounting standards had been followed along with proper explanation relating to material departures;
- (b) the directors had selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company at the end of the financial year and of the profit and loss for that period;
- (c) the directors had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of this Act for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;
- (d) the directors had prepared the annual accounts on a going concern basis; and

DNDi Drugs for Neglected Diseases initiative
India Foundation

(CIN: U73100DL2016NPL300545)

Registered Office: PHD Chamber, 3rd Floor, 4/2 Siri Institutional Area, August Kranti Marg, New Delhi 110016, India

Ph: +91-11-45501795; E-mail: dndiindiafoundation@gmail.com

- (e) the directors had devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

Auditors

M/s. Singh K.V. Gupta & Co., Chartered Accountants, Statutory Auditors of the Company, hold office until the conclusion of the sixth Annual General Meeting and their appointment would be required to be ratified at the ensuing annual general meeting.

Auditors' Report

The Auditor's Report for the period has been annexed with this report and the comments made by the Statutory Auditors in the Auditor's Report are self-explanatory.

Statement concerning development and implementation of risk management policy of the Company

In the opinion of the Board of Directors of the Company, no risks which may threaten the existence of the Company have been identified and therefore no risk management policy has been framed.

Subsidiaries, joint ventures and associate Companies

The Company does not have any Subsidiary, Joint Venture or Associate Company.

Details of significant & material orders passed by the regulators, courts, tribunals impacting the going concern status and Company's operations in future

No significant & material order has been passed by the regulators, courts, tribunals impacting the going concern status and Company's operations in future.

Adequacy of internal financial controls

The Company has in place adequate internal financial controls with reference to financial statements. During the year under review, such controls were tested and no reportable material weakness in the design or operation were observed.

Maintenance of cost records

The Company is not required to maintain cost records as specified by the Central Government under section 148(1) of the Companies Act, 2013.


Internal Complaints Committee under the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013

The Company is not required to constitute Internal Complaints Committee under the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013.

Acknowledgment

Your Directors take this opportunity to place on record their sincere appreciation for the co-operation and assistance the Company has received from banks and various Government Departments.

For and on behalf of the Board of Directors of
DNDi Drugs for Neglected Diseases Initiative India Foundation


(Lalit Kant)
Director


(Unni Krishnan Karunakara)
Director

DNDi Drugs for Neglected Diseases *initiative*
India Foundation

(CIN: U73100DL2016NPL300545)

Registered Office: PHD Chamber, 3rd Floor, 4/2 Sri Institutional Area, August Kranti Marg, New Delhi 110015, India

Ph: +91-11-45501795; E-mail: dndiindiafoundation@gmail.com

DIN: 07242018

Address: B-95, Block B, Gulmohar Park,
New Delhi – 110049, India

Date: August 21, 2018

Place: New Delhi

DIN: 07241987

Address: PULIVELIL KAROOR
AMBALAPUZHA, KERALA - 688561
INDIA

Date: August 21, 2018

Place: New Delhi

DNDi Drugs for Neglected Diseases initiative
India Foundation

(CIN: U73100DL2016NPL300545)

Registered Office: PHD Chamber, 3rd Floor, 4/2 Siri Institutional Area, August Kranti Marg, New Delhi 110016, India
Ph: +91-11-45501795; E-mail: dndiindiafoundation@gmail.com

ANNEXURE A

Form No. MGT-9

EXTRACT OF ANNUAL RETURN

As on the financial year ended on March 31, 2017

[Pursuant to Section 92(3) of the Companies Act, 2013 and rule 12(1) of the Companies
(Management and Administration) Rules, 2014]

I. REGISTRATION AND OTHER DETAILS:

- i) CIN: U73100DL2016NPL300545
- ii) Registration Date: May 27, 2016
- iii) Name of the Company: DNDi Drugs for Neglected Diseases Initiative India Foundation
- iv) Category / Sub-Category of the Company: Section 8 company (not for profit) Company limited by guarantee not having share capital
- v) Address of the Registered office and contact details:
Registered office: PHD Chamber, 3rd Floor 4/2 Siri Institutional Area, August Kranti Marg,
New Delhi - 110016 India
Contact details:
Telephone No: +91 (11) 4550-1795
Mail id: dndiindiafoundation@gmail.com
- vi) Whether listed company: No
- vii) Name, Address and Contact details of Registrar and Transfer Agent, if any: Not Applicable

II. PRINCIPAL BUSINESS ACTIVITIES OF THE COMPANY

DNDi Drugs for Neglected Diseases Initiative India Foundation is a section 8 company and is incorporated with the aim of providing support and to stimulate research and development, primarily of drugs, as well as vaccines and diagnostics for patients suffering from neglected diseases.

All the business activities contributing 10 % or more of the total turnover of the company shall be stated:-

Sl. No.	Name and Description of main products services	NIC Code of the Product/ service	% to total turnover of the company
1	NIL	-	NIL

III. PARTICULARS OF HOLDING, SUBSIDIARY AND ASSOCIATE COMPANIES – Not Applicable

S. No.	Name and Address of the Company	CIN/GLN	Holding/ Subsidiary/ Associate	% Of Shares Held	Applicable Section
			N.A.		

(CIN: U73100DL2016NPL300545)

Ph: +91-11-45501795; E-mail: dndiindiafoundation@gmail.com

Not Applicable as DNDI Drugs for Neglected Diseases Initiative India Foundation is a section 8 company limited by guarantee not having a share capital.

[illegible]

(CTN: U73700DL2016NPL300545)

Ph: +91-11-43501795; E-mail: dadundiafoundation@gmail.com

DNDi Drugs for Neglected Diseases initiative
India Foundation

(CIN: U73100DL2016NPL300545)

Registered Office: PhD Chamber, 3rd Floor, 4/2 Siri Institutional Area, August Kranti Marg, New Delhi 110016, India
 Pk: +91-11-45501795; E-mail: dndiindiafoundation@gmail.com

iv. Overseas									
d) Individual									
i. Individual Shareholders holding nominal share capital upto Rs. 1 Lakh									
ii. Individual shareholders holding nominal share capital in excess of Rs. 1 lakh									
e) Others (specify)									
Sub-total (B) (2):-									
Total Public Shareholding (B)=(B)(1)+ (B)(2)									
C. Shares held by Custodian for GDRs & ADRs									
Grand Total (A+B+C)									

ii. Shareholding of Promoters

Sl. No.	Shareholder's name	Shareholding at the beginning of the year			Shareholding at the end of the year			% change in shareholding during the year
		No. of Shares	% of total Shares of the company	% of Shares Pledged / encumbered to total shares	No. of Shares	% of total Shares of the company	% of Shares Pledged / encumbered to total shares	

iii. Change in Promoters' Shareholding (please specify, if there is no change)

Sl. No.		Shareholding at the beginning of the year		Cumulative Shareholding during the year	
		No. of shares	% of total shares of the company	No. of shares	% of total shares of the company
	At the beginning of the year				

DNDi Drugs for Neglected Diseases initiative
India Foundation

(CIN: U73100DL2016NPL300545)

Registered Office: PHD Chamber, 3rd Floor, 4/2 Sri Institutional Area, August Kranti Marg, New Delhi 110016, India

Ph: +91-11-45501795; E-mail: dndiindiafoundation@gmail.com

	Date wise Increase / Decrease in Promoters Shareholding during the year specifying the reasons for increase / decrease (e.g. allotment / transfer / bonus/ sweat equity etc):				
	At the end of the year				

iv. Shareholding Pattern of top ten Shareholders (other than Directors, Promoters and Holders of GDRs and ADRs):

Sl. No.		Shareholding at the beginning of the year		Cumulative Shareholding during the year	
	For Each of the Top 10 Shareholders	No. of shares	% of total shares of the company	No. of shares	% of total shares of the company
	At the beginning of the year				
	Date wise Increase / Decrease in Shareholding during the year specifying the reasons for increase / decrease (e.g. allotment / transfer / bonus / sweat equity etc):				
	At the End of the year (or on the date of separation, if separated during the year)				

V. INDEBTEDNESS

Indebtedness of the Company including interest outstanding/accrued but not due for payment

	Secured Loans excluding deposits	Unsecured Loans	Deposits	Total Indebtedness
Indebtedness at the beginning of the financial year				
i) Principal Amount	Nil	Nil	Nil	Nil
ii) Interest due but not paid	Nil	Nil	Nil	Nil
iii) Interest accrued but not due	Nil	Nil	Nil	Nil
Total (i+ii+iii)	Nil	Nil	Nil	Nil

DNDi Drugs for Neglected Diseases initiative
India Foundation

(CIN: U73100DL2016NPL300545)

Registered Office: PHD Chamber, 3rd Floor, 4/2 Siri Institutional Area, August Kranti Marg, New Delhi 110016, India
 P/c: +91-11-45901795; E-mail: dndiindiafoundation@gmail.com

Change in Indebtedness during the financial year				
• Addition	Nil	Nil	Nil	Nil
• Reduction	Nil	Nil	Nil	Nil
Net Change	Nil	Nil	Nil	Nil
Indebtedness at the end of the financial year				
i) Principal Amount	Nil	Nil	Nil	Nil
ii) Interest due but not paid	Nil	Nil	Nil	Nil
iii) Interest accrued but not due	Nil	Nil	Nil	Nil
Total (i+ii+iii)	Nil	Nil	Nil	Nil

VI. REMUNERATION OF DIRECTORS AND KEY MANAGERIAL PERSONNEL

A. Remuneration to Managing Director, Whole-time Directors and/or Manager: Not Applicable

Sl. No.	Particulars of Remuneration	Name of MD/WT/ Manager	Total Amount
1	Gross salary		
	• Salary as per provisions contained in section 17(1) of the Income		
	• Value of perquisites u/s 17(2) Income		
	• Profits in lieu of salary under section 17(3) Income		
2	Stock Option		
3	Sweat Equity		
4	Commission		
	• As % of profit		
	• Others specify ...		
5	Others, please specify		
	Total (A)		
	Ceiling as per the Act		

DNDi Drugs for Neglected Diseases initiative
India Foundation

(CIN: U73100DL2016NPL300543)

Registered Office: PHD Chamber, 3rd Floor, 4/2 Siri Institutional Area, August Kranti Marg, New Delhi 110016, India
 Pl: +91-11-45501795; E-mail: dndiindiafoundation@gmail.com

B. Remuneration to other directors: Not Applicable

Sl. No.	Particulars of Remuneration	Name of Directors	Total Amount
	1. Independent Directors		
	• Fee for attending board/committee meetings.		
	• Commission		
	• Others, please specify		
	Total (1)		
	2. Other Non-Executive Directors		
	• Fee for attending board/committee meetings.		
	• Commission		
	• Others, please specify Annual remuneration (pro-rated) Expenses		
	Total (2)		
	Total (B) = (1+2)		
	Total Managerial Remuneration		
	Overall Ceiling as per the Act		

C. REMUNERATION TO KEY MANAGERIAL PERSONNEL OTHER THAN MD/MANAGER/WTD: Not applicable

Sl. No.	Particulars of Remuneration	Key Managerial Personnel			
		CEO	Company Secretary	CFO	Total
1	Gross salary				
	• Salary as per provisions contained in section 17(1) of the Income				
	• Value of perquisites u/s 17(2) Income				
	• Profits in lieu of salary under section 17(3) Income				
2	Stock Option				
3	Sweat Equity				
4	Commission				

**DNDi Drugs for Neglected Diseases initiative
India Foundation**

(CIN: U73100DL2016NPL300545)

Registered Office: PHD Chamber, 3rd Floor, 4/2 Siri Institutional Area, August Kranti Marg, New Delhi-110016, India
Ph: +91-11-45501795; E-mail: dndindiafoundation@gmail.com

	• As % of profit				
	• Others, specify				
5	Others, please specify				
	Total				

VII. PENALTIES / PUNISHMENT / COMPOUNDING OF OFFENCES: Not Applicable

Type	Section of the Companies Act	Brief Description	Details of Penalty / Punishment/ Compounding fees imposed	Authority [RD / NCLT/ COURT]	Appeal made, if any (give Details)
------	------------------------------	-------------------	---	------------------------------	------------------------------------

A. COMPANY

Penalty					
Punishment					
Compounding					

B. DIRECTORS

Penalty					
Punishment					
Compounding					


C. OTHER OFFICERS IN DEFAULT

Penalty					
Punishment					
Compounding					

For and on behalf of the Board of Directors of
DNDi Drugs for Neglected Diseases Initiative India Foundation


(Lalit Kant)
Director
DIN: 07242018
Address: B-95, Block B, Gulmohar Park,
New Delhi - 110049, India

Date: August 21, 2018
Place: New Delhi


(Unni Krishnan Karunakara)
Director
DIN: 07241987
Address: PULIVELIL KAROOR
AMBALAPUZHA, KERALA - 688561
INDIA
Date: August 21, 2018
Place: New Delhi



INDEPENDENT AUDITOR'S REPORT

To

The Members

DNDI Drugs for Neglected Diseases Initiative India Foundation

New Delhi

Report on the Standalone Financial Statements

We have audited the accompanying Standalone financial statements of **DNDI Drugs for Neglected Diseases Initiative India Foundation** ("the Company"), which comprise the Balance Sheet as at **31st March, 2018**, the Statement of Income & Expenditure Account, the Cash Flow Statement for the year then ended, and a summary of the significant accounting policies and other explanatory information.

Management's Responsibility for the Standalone Financial Statements and for Internal Financial Controls over Financial Reporting

The Company's Board of Directors is responsible for the matters stated in Section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these standalone financial statements that give a true and fair view of the financial position, financial performance and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from

Page | 1



material misstatement, whether due to fraud or error.

The Company's management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India (ICAI). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Act.

Auditor's Responsibility

Our responsibility is to express an opinion on these standalone financial statements based on our audit and to express an opinion on the Company's internal financial controls over financial reporting based on our audit.

We have taken into account the provisions of the Act, the accounting and auditing standards and matters which are required to be included in the audit report under the provisions of the Act and the Rules made there under.

We conducted our audit in accordance with the Standards on Auditing specified under Section 143(10) of the Act and the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting. Those Standards and Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement and whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the financial statements and adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of



internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal financial control relevant to the Company's preparation of the financial statements that give a true and fair view in order to design audit procedures that are appropriate in the circumstances. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the accounting estimates made by the Company's Directors, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the standalone financial statements and unqualified opinion on the Company's internal financial controls system over financial reporting.

Meaning of Internal Financial Controls Over Financial Reporting

A company's internal financial controls over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial controls over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.



Inherent Limitations of Internal Financial Controls Over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at 31st March, 2018, and its deficit and its cash flows for the year ended on that date.

Report on Other Legal and Regulatory Requirements

- 1) Companies (Auditor's Report) Order, 2016 ("The Order") issued by the Central Government of India in terms of sub section (11) of Section 143 of the Act is not applicable to the Company as the Company was licensed to operate u/s 8 of the Companies Act 2013.
- 2) As required by Section 143 (3) of the Act, we report that:
 - (a) We have sought and obtained all the information and explanations which to the best



of our knowledge and belief were necessary for the purposes of our audit.

- (b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books
- (c) The Balance Sheet, the Statement of Income & Expenditure, and the Cash Flow Statement dealt with by this Report are in agreement with the books of account
- (d) In our opinion, the aforesaid standalone financial statements comply with the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014
- (e) On the basis of written representations received from the directors as on 31st March 2018 taken on records by the Board of Directors, none of the directors is disqualified as on 31st March 2018 from being appointed as director in terms of section 164(2) of the Companies Act 2013.
- (f) In our opinion considering nature of business, size of operation and organisational structure of the entity, adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at 31st March 2018, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.
- (g) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:

- i. the Company does not have any pending litigations which would impact its



financial position.

- ii. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.
- iii. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.

For Singh K.V. Gupta & Co

Chartered Accountants

Firm's Registration Number: 000133N



CA RAKESH K AGARWAL
Partner
(M. No. 085908)

Place of Signature: New Delhi
Date :21st Aug. 2018

DNDI DRUGS FOR NEGLECTED DISEASES INITIATIVE INDIA FOUNDATION
PHD CHAMBERS, 3RD FLOOR, 4/2, INSTITUTIONAL AREA, AUGUST KRANTI MARG, NEW DELHI--110049
 (A Private Company limited by guarantee under section 8 of the Companies Act 2013)
BALANCE SHEET AS AT MARCH 31, 2018

Particulars	Note No.	As at 31.03.2018 Rs.	As at 31.03.2017 Rs.
EQUITY AND LIABILITIES			
Member's funds			
Reserves and surplus	2	(76,009)	(39,876)
		(76,009)	(39,876)
Current liabilities			
Other current liabilities	3	87,900	57,500
TOTAL		11,891	17,624
ASSETS			
Non-current assets			
Fixed assets	4		
- Tangible assets		2,457	3,315
- Intangible assets		0	0
- Capital work in progress		0	0
		2,457	3,315
Current assets			
Cash and cash equivalents	5	9,434	14,308
TOTAL		11,891	17,623

Accompanying notes 1 to 9 form part of the financial statements

In terms of our report attached
 For Singh K.V. Gupta & Co
 Chartered Accountants
 Firm Registration No. 000133N

CA. Rakesh K. Agarwal
 Partner
 M.No. 085908
 Place : New Delhi
 Date : 25 Aug 2018



For and on behalf of the board

Unni Krishnan Karunakara
 Director
 DIN:07241987

Lalit Kant
 Director
 DIN:07242018

DNDI DRUGS FOR NEGLECTED DISEASES INITIATIVE INDIA FOUNDATION
 PHD CHAMBERS, 3RD FLOOR, 4/2, INSTITUTIONAL AREA, AUGUST KRANTI MARG, NEW DELHI-110049
 (A Private Company limited by guarantee under section 8 of the Companies Act 2013)

STATEMENT OF INCOME AND EXPENDITURE FOR THE YEAR ENDED MARCH 31, 2018

Particulars	Note No.	Year ended 31.03.2018 Rs.	Year ended 31.03.2017 Rs.
REVENUE			
Income from Operation	6	-	64,011
Other Income	7	350	132
TOTAL REVENUE		350	64,143
EXPENSES			
Programme/Project Expenses	8	-	46,460
Other Expenses	9	35,625	57,500
Depreciation	4	858	60
TOTAL EXPENSES		36,483	1,04,020
Surplus(Deficit) for the year		(36,133)	(39,877)

Accompanying notes 1 to 9 form part of the financial statements

In terms of our report attached
 For Singh K.V. Gupta & Co
 Chartered Accountants
 Firm Registration No. 000133N

CA. Rakesh K. Agarwal
 Partner
 M.No. 085908
 Place : New Delhi
 Date 2/ Aug. 2018



For and on behalf of the board

Unni Krishnan Karunakara
 Director
 DIN:07241987

Lalit Kant
 Director
 DIN:07242018

DND: DRUGS FOR NEGLECTED DISEASES INITIATIVE INDIA FOUNDATION
(A Private Company limited by guarantee under section 8 of the Companies Act 2013.)
CASH FLOW STATEMENT FOR THE YEAR ENDED 31ST MARCH 2018

Rupees in '000'

	YEAR ENDED 31-03-2018	YEAR ENDED 31-03-2017
A CASH FLOW FROM OPERATING ACTIVITIES		
SURPLUS/DEFICIT BEFORE TAX AND EXTRAORDINARY ITEMS	-36.13	-39.88
ADJUSTMENT FOR		
DEPRECIATION	0.86	0.08
DEPRECIATION RESERVE	-	-
FINANCE CHARGES	-	-
INTEREST ON BANK DEPOSIT/ LOANS & ADVANCE	-0.35	-0.13
PROVISION FOR INCOME TAX	-	-
DEFERRED TAX ASSETS	-	-
TAX ON DIVIDEND	-	-
CAPITAL CHANGES	-35.62	-39.95
ADJUSTMENT FOR		
(INCREASE) / DECREASE IN SUNDRY DEBTORS	-	-
(INCREASE) / DECREASE IN INVENTORIES	-	-
(INCREASE) / DECREASE IN NON CURRENT ASSETS	-	-
(INCREASE) / DECREASE IN LOANS & ADVANCES	-	-
(INCREASE) / (DECREASE) IN CURRENT LIABILITIES	30.40	57.50
NET CASH FLOW FROM OPERATING ACTIVITIES	-5.22	17.55
B CASH FLOW FROM INVESTING ACTIVITIES		
ADDITION TO FIXED ASSETS	-	-3.38
SALE OF FIXED ASSETS	-	-
ADDITION TO WORK IN PROGRESS	-	-
INTEREST ON BANK DEPOSITS / LOANS & ADVANCES	0.35	0.13
NET CASH USED IN INVESTING ACTIVITIES	0.35	-3.25
C CASH FLOW FROM FINANCING ACTIVITIES		
SHARE CAPITAL	-	-
SHARE APPLICATION MONEY PENDING ALLOTMENT	-	-
INVESTMENTS	-	-
DIVIDEND AND TAX ON DIVIDEND PAID	-	-
INCOME TAX PAID	-	-
FINANCING CHARGES	-	-
NET CASH GENERATED/USED FROM FINANCING ACTIVITIES	-	-
NET INCREASE / (DECREASE) IN CASH AND CASH EQUIVALENTS (A+B+C)	-4.87	14.31
CASH & CASH EQUIVALENTS AS AT OPENING DATE	14.31	-
	9.44	14.31
CASH & CASH EQUIVALENTS AS AT CLOSING DATE	9.44	14.31

As per our report of even date attached
For Singh K. V. Gupta & Co.
Chartered Accountants
FRN 000133N

For & on behalf of the Board


(CA Rakesh K. Agarwal)
Partner
Membership No. 085908
Place : New Delhi
Date: 2/ Aug 2018


Unni Krishnan Karunakara
Director
DIN: 07241987


Lalit Kant
Director
DIN: 07242018

DNDI DRUGS FOR NEGLECTED DISEASES INITIATIVE INDIA FOUNDATION
(A Private Company Limited by Guarantee under section 8 of the Companies Act, 2013)
PHD Chambers, 3rd Floor, 4/2, Institutional Area, August Kranti Marg, New Delhi-110049
Tel:- 011-45501795

Note – 1: SIGNIFICANT ACCOUNTING POLICIES:

A: ACCOUNTING CONCEPT

The accounts are prepared on historical cost convention on accrual basis and also on a going concern basis in accordance with Generally Accepted Accounting Principles and accounting standards applicable in India as applicable under section 133 of the Companies Act 2013 read with MCA General Circular No. 15/2013 dated 13th September 2013 and other relevant provision of the Indian Companies Act 2013 read with the Companies (Accounts) Rules, 2014 except where otherwise stated.

B. USE OF ESTIMATES

The preparation of financial statements in conformity with the generally accepted accounting practices requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent liabilities at the date of the financial statements and the results of operations during the reporting year. Actual results could differ from those estimates. Differences between the actual results and estimates are recognised in the year in which the results are known/ materialized. Any revision to accounting estimates is recognised prospectively in current and future periods.

Contingencies are recorded when it is probable that a liability will be incurred and the amount can be reasonably estimated.

C: FIXED ASSETS AND DEPRECIATION

Fixed Assets are stated at their original cost including freight, duties, customs and other incidental expenses relating to acquisition, installation and construction. Depreciation has been provided on written down value method over the useful life of Assets as specified in Schedule-II to the Companies Act 2013

D: REVENUE RECOGNITION

- 1) Grants and donations are recognized in the financial statements only when the same are sanctioned by the concerned agencies and received by the Company.
- 2) Interest on saving banks is recognized whenever same is credited by bank in the account of the Company.



E: Grants made to projects carried out through partner agencies are accounted for on the basis of utilization certificate/statement submitted by the grantees.

F: FOREIGN EXCHANGE TRANSACTIONS

Transactions in foreign currencies are recorded at the rate at which credit/ debit is given by the bank at the time of occurrence of the transaction.

G: PROVISIONS

A provision is recognized when an enterprise has a present obligation as a result of past event; it is probable that an outflow of resources will be required to settle the obligation, in respect of which a reliable estimate can be made. Provisions are not discounted to its present value and are determined based on best estimate required to settle the obligation at the balance sheet date. These are reviewed at each balance sheet date and adjusted to reflect the current best estimates.

H: OTHERS


Accounting Policies not specifically referred to otherwise are consistent with generally accepted accounting principles followed by the Company.



NOTES TO THE ACCOUNTS:

- A: This is the Second Year of the Company as the Company was incorporated on 27th May 2016 as a private company limited by guarantee and not having a share capital and was granted a license no. 107097 dated 23rd May 2016 under section 8(1) of the Companies Act, 2013, by Government of India- Ministry of Corporate Affairs. The Company has been granted registration under section 12AA of the Income Tax Act 1961 vide letter no CIT (E)/DEL-DR26044-23032017/7387 dated 23rd March 2017 & approval under section 80-G of the Income Tax Act 1961 vide letter no. CIT(E)/DEL-DE27667-23032017/8506 dated 23rd March 2017 by Commission of Income Tax (Exemption) Delhi
- B: Amount due from Director Rs.NIL
- C: Provision for taxation has not been made in accounts in the absence of any income.
- D: The Company is a Small and Medium Sized Company (SMC) as defined in the General Instructions in respect of Accounting Standards notified under the Companies Act, 1956. Accordingly, the Company has complied with the Accounting Standards as applicable to a Small and Medium Sized Company.
- E: Notes A to D form an integral part of the balance sheet and income & expenditure account.

For and on behalf of the Board of Directors
Of DNDI Drugs for Neglected Diseases Initiative India Foundation



Unni Krishnan Karunakara
Director
DIN:07241987



Lalit Kant
Director
DIN:07242018

Date : Aug. 2018
Place : New Delhi



DNDI DRUGS FOR NEGLECTED DISEASES INITIATIVE INDIA FOUNDATION
(A Private Company limited by guarantee under section 8 of the Companies Act 2013)

2 Reserves and surplus

	As at 31.03.2018	As at 31.03.2017
	Rs.	

(a) Surplus in Statement of Income & Expenditure Account

Opening balance	(39,877)	0
Add: Excess of income over expenditure	(36,135)	(39,877)
Closing balance	(76,012)	(39,877)

3 Other current liabilities

	As at 31.03.2018	As at 31.03.2017
	Rs.	Rs.
Payable to related party	0	0
TDS Payable	0	5,000
Audit Fees Payable	87,900	52,500
	87,900	57,500



DNDI DRUGS FOR NEGLECTED DISEASES INITIATIVE INDIA FOUNDATION

(A Private Company limited by guarantee under section 8 of the Companies Act 2013)

Notes to the accounts (continued)

4 Fixed Assets

(Amount in INR)

Particulars	GROSS BLOCK			DEPRECIATION				Net block	
	As at 01.04.2017	Additions	Deductions	As at 31.03.2018	As at 01.04.2017	For the year	On deductions	As at 31.03.2018	As at 31.03.2017
Tangible Assets									
Furniture & Fixture	3375	0	0	3375	60	858	0	918	3315
Total Tangible Assets	3375	0	0	3375	60	858	0	918	3315
Intangible Assets	0	0	0	0		0	0	0	0
Capital - work - in progress	0	0	0	0		0	0	0	0
Previous Year's Figures	0	3375	0	3375	0	60	0	3315	0



ONDI DRUGS FOR NEGLECTED DISEASES INITIATIVE INDIA FOUNDATION
(A Private Company limited by guarantee under section 8 of the Companies Act 2013)

Notes to the accounts (continued)

5. Cash and cash equivalents

	As at 31.03.2018 Rs.	As at 31.03.2017 Rs.
Balances with banks		
- Saving accounts	5,434	4,368
Cash in hand	0	9,540
	<u>9,434</u>	<u>14,308</u>

6. Revenue from Operations

	As at 31.03.2018 Rs.	As at 31.03.2017 Rs.
Donation received	0	64,011
	<u>0</u>	<u>64,011</u>

7. Other Income

	As at 31.03.2018 Rs.	As at 31.03.2017 Rs.
Saving Bank Interest	350	132
	<u>350</u>	<u>132</u>

8. Programme/Project Expenses

	As at 31.03.2018 Rs.	As at 31.03.2017 Rs.
Asha Worker's Training Expenses	0	28,360
Conveyance to participants & trainer	0	18,100
	<u>0</u>	<u>46,460</u>

9. Other expenses

	As at 31.03.2018 Rs.	As at 31.03.2017 Rs.
Auditors' remuneration		
- As auditors	30,000	50,000
- Service tax/GST on above	5,400	7,500
Interest on TDS	225	0
	<u>35,625</u>	<u>57,500</u>

